Physician profile
William E Boyd
NPI 1255335899
$288.44
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.65 · 2020: $49.45 · 2021: $70.13 · 2022: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $90.86 | 2021-2022 | |
| Glaxosmithkline, LLC. | $67.56 | 2019-2022 | |
| Pfizer INC. | $65.35 | 2019-2021 | |
| Sobi, INC | $35.33 | 2022 | |
| Shire North American Group INC | $14.68 | 2019 | |
| Merck Sharp & Dohme LLC | $14.66 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.